Wei Wang1, Meifeng Zhou2, Yuebo Liang1, Fan Zhang1, Zhong Wu3, Shaowei Mo4* and Yi Qing Wang1*
... developed resistance of trastuzumab remained a problem for clinical therapy of HER2-positive breast cancer. However, effects of YAP/TAZ pathway on resistance of trastuzumab have not been explored. Tumor tissues were collected from 40 breast cancer patients for clinical studies. For in vitro studies, human breast cancer cell lines SK-BR-3-TS was obtained, and trastuzumab resistant model SK...
Xiaowei Zhang*
...utic drugs, apatinib and trastuzumab, on gastric cancer with ascites. 225 patients with gastric cancer and ascites received by the Oncology Department and Gastrointestinal Department of the Central Hospital during October 2019-2021 were selected. They were subsequently assigned into apatinib group, trastuzumab group and combined treatment group. Compared with other treatment groups, the long-term and short-term survival rate...
Biao Zhong1*, MengMeng Zou1, Jie Zeng1, Juan Bai2, YongJun Deng3, Xin Li4 and YongQin Wang5
...tional chemotherapy with trastuzumab combined with docetaxel (TCD), were enrolled in the study, which was conducted from January 2021 to March 2022. Patients were randomly assigned to receive combination therapy with Pyrotinib and TCD (observation group) or TCD chemotherapy (control group) in a 1:1 ratio. Changes in CEA, CA15-3, and CA125 levels at pre-treatment (T0), after 2 treatment cycles (T1), and after 4 treatment cycles (T2), as well as safety parameter...
